Franca Falzetti
Overview
Explore the profile of Franca Falzetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guardalupi F, Sorrentino C, Corradi G, Giancola R, Baldoni S, Ulbar F, et al.
Leukemia
. 2023 Jun;
37(7):1572-1575.
PMID: 37286785
No abstract available.
2.
Martelli M, Rossi R, Venanzi A, Meggendorfer M, Perriello V, Martino G, et al.
Blood
. 2021 Aug;
138(25):2696-2701.
PMID: 34343258
Nucleophosmin (NPM1) mutations in acute myeloid leukemia (AML) affect exon 12, but also sporadically affect exons 9 and 11, causing changes at the protein C-terminal end (tryptophan loss, nuclear export...
3.
Gionfriddo I, Brunetti L, Mezzasoma F, Milano F, Cardinali V, Ranieri R, et al.
Leukemia
. 2021 Mar;
35(9):2552-2562.
PMID: 33654209
Acute myeloid leukemia (AML) with mutated NPM1 accounts for one-third of newly diagnosed AML. Despite recent advances, treatment of relapsed/refractory NPM1-mutated AML remains challenging, with the majority of patients eventually...
4.
Pierini A, Ruggeri L, Carotti A, Falzetti F, Saldi S, Terenzi A, et al.
Blood Adv
. 2021 Mar;
5(5):1199-1208.
PMID: 33646302
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed...
5.
Ulbar F, Villanova I, Giancola R, Baldoni S, Guardalupi F, Fabi B, et al.
Biol Blood Marrow Transplant
. 2020 Sep;
26(12):2204-2210.
PMID: 32961369
In the setting of T cell-depleted, full-haplotype mismatched transplantation, adoptive immunotherapy with regulatory T cells (Tregs) and conventional T cells (Tcons) can prevent graft-versus-host disease (GVHD) and improve post-transplantation immunologic...
6.
Del Papa B, Baldoni S, Dorillo E, De Falco F, Rompietti C, Cecchini D, et al.
Clin Cancer Res
. 2019 Oct;
25(24):7540-7553.
PMID: 31578228
Purpose: Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant...
7.
Pierini A, Ruggeri L, Carotti A, Falzetti F, Piccinelli S, Saldi S, et al.
Bone Marrow Transplant
. 2019 Aug;
54(Suppl 2):803-805.
PMID: 31431718
No abstract available.
8.
Pierini A, Ruggeri L, Mancusi A, Carotti A, Falzetti F, Terenzi A, et al.
Bone Marrow Transplant
. 2019 Aug;
54(Suppl 2):775-779.
PMID: 31431701
Allogeneic hematopoietic cell transplantation from a human leukocyte antigen (HLA) haplotype mismatched donor (haploidentical transplantation) was not feasible for the treatment of hematologic malignancies until the early 1990s, due to...
9.
Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska M, Abruzzese E, et al.
Ann Hematol
. 2019 Aug;
98(10):2329-2338.
PMID: 31392461
Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data...
10.
Borghi L, Galimberti S, Barate C, Bonifacio M, Capochiani E, Cuneo A, et al.
Front Psychol
. 2019 Mar;
10:329.
PMID: 30842749
The main objective of this study is to gain further insights on how chronic myeloid leukemia (CML) patients involved in an interventional clinical trial with the purpose of reaching treatment...